Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sj√∂gren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “

Several other equities analysts also recently commented on ANTH. Piper Jaffray Companies lowered their price objective on Anthera Pharmaceuticals from $7.00 to $1.35 and set an “overweight” rating on the stock in a research report on Thursday, December 29th. Jefferies Group downgraded Anthera Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price objective for the company from $5.00 to $1.00 in a research report on Thursday, December 29th. Citigroup Inc. cut Anthera Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Thursday, December 29th. SunTrust Banks, Inc. cut Anthera Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their target price for the stock from $6.00 to $1.00 in a report on Wednesday, December 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price (down from $10.00) on shares of Anthera Pharmaceuticals in a report on Thursday, December 29th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $3.48.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/01/11/anthera-pharmaceuticals-inc-anth-upgraded-by-zacks-investment-research-to-hold.html

Anthera Pharmaceuticals (NASDAQ:ANTH) traded down 5.5050% during mid-day trading on Wednesday, reaching $0.6746. The company had a trading volume of 1,508,816 shares. The firm’s 50-day moving average is $1.57 and its 200-day moving average is $2.63. Anthera Pharmaceuticals has a one year low of $0.64 and a one year high of $4.90. The firm’s market capitalization is $28.30 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.23. On average, equities research analysts anticipate that Anthera Pharmaceuticals will post ($1.59) earnings per share for the current fiscal year.

WARNING: “Anthera Pharmaceuticals, Inc. (ANTH) Upgraded by Zacks Investment Research to Hold” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was copied illegally and republished in violation of US & international copyright and trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/01/11/anthera-pharmaceuticals-inc-anth-upgraded-by-zacks-investment-research-to-hold.html.

Large investors have recently modified their holdings of the company. Rhumbline Advisers boosted its stake in shares of Anthera Pharmaceuticals by 0.5% in the third quarter. Rhumbline Advisers now owns 56,699 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 310 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Anthera Pharmaceuticals by 0.3% in the second quarter. Bank of New York Mellon Corp now owns 230,767 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 645 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Anthera Pharmaceuticals by 1.2% in the third quarter. California State Teachers Retirement System now owns 83,243 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 1,000 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Anthera Pharmaceuticals by 3.4% in the second quarter. ProShare Advisors LLC now owns 35,319 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,168 shares during the last quarter. Finally, HighTower Advisors LLC boosted its stake in shares of Anthera Pharmaceuticals by 8.0% in the second quarter. HighTower Advisors LLC now owns 50,100 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 3,700 shares during the last quarter. 51.11% of the stock is currently owned by hedge funds and other institutional investors.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

5 Day Chart for NASDAQ:ANTH

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.